Evolus Debt to Equity Ratio 2016-2025 | EOLS
Current and historical debt to equity ratio values for Evolus (EOLS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Evolus debt/equity for the three months ending March 31, 2025 was 22.00.
| Evolus Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.22B | $-0.01B | -33.31 |
| 2024-12-31 | $0.23B | $0.01B | 41.12 |
| 2024-09-30 | $0.22B | $0.01B | 37.98 |
| 2024-06-30 | $0.21B | $0.02B | 11.10 |
| 2024-03-31 | $0.21B | $0.02B | 11.26 |
| 2023-12-31 | $0.21B | $-0.02B | -10.14 |
| 2023-09-30 | $0.19B | $-0.02B | -9.67 |
| 2023-06-30 | $0.18B | $-0.01B | -25.27 |
| 2023-03-31 | $0.15B | $0.01B | 22.06 |
| 2022-12-31 | $0.16B | $0.02B | 8.62 |
| 2022-09-30 | $0.16B | $0.03B | 5.60 |
| 2022-06-30 | $0.16B | $0.05B | 3.50 |
| 2022-03-31 | $0.15B | $0.07B | 2.28 |
| 2021-12-31 | $0.18B | $0.08B | 2.15 |
| 2021-09-30 | $0.12B | $0.10B | 1.21 |
| 2021-06-30 | $0.13B | $0.11B | 1.26 |
| 2021-03-31 | $0.13B | $0.02B | 5.75 |
| 2020-12-31 | $0.28B | $-0.07B | -3.87 |
| 2020-09-30 | $0.18B | $0.04B | 5.15 |
| 2020-06-30 | $0.15B | $0.04B | 3.46 |
| 2020-03-31 | $0.15B | $0.06B | 2.42 |
| 2019-12-31 | $0.16B | $0.08B | 2.03 |
| 2019-09-30 | $0.17B | $0.02B | 9.72 |
| 2019-06-30 | $0.16B | $0.04B | 3.92 |
| 2019-03-31 | $0.15B | $0.08B | 1.93 |
| 2018-12-31 | $0.09B | $0.08B | 1.04 |
| 2018-09-30 | $0.09B | $0.10B | 0.93 |
| 2018-06-30 | $0.08B | $0.04B | 2.21 |
| 2018-03-31 | $0.08B | $0.05B | 1.45 |
| 2017-12-31 | $0.23B | $-0.08B | -3.02 |
| 2017-09-30 | $0.00B | $0.00B | 0.00 |
| 2017-06-30 | $0.00B | $0.00B | 0.00 |
| 2017-03-31 | $0.00B | $0.00B | 0.00 |
| 2016-12-31 | $0.09B | $-0.01B | -11.92 |
| 2015-12-31 | $0.07B | $0.01B | 5.77 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.616B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.788B | 27.51 |
| Boston Scientific (BSX) | United States | $154.602B | 38.70 |
| Stryker (SYK) | United States | $144.385B | 30.19 |
| EssilorLuxottica (ESLOY) | France | $135.514B | 0.00 |
| Medtronic (MDT) | Ireland | $103.771B | 14.71 |
| Haleon (HLN) | United Kingdom | $49.845B | 28.36 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.977B | 0.00 |
| ResMed (RMD) | United States | $35.996B | 27.04 |
| GE HealthCare Technologies (GEHC) | United States | $31.796B | 15.10 |
| Agilent Technologies (A) | United States | $31.270B | 20.66 |
| Terumo (TRUMY) | Japan | $27.864B | 36.19 |
| Insulet (PODD) | United States | $22.590B | 88.67 |
| Koninklijke Philips (PHG) | Netherlands | $21.684B | 15.59 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.137B | 11.65 |
| Baxter (BAX) | United States | $15.534B | 11.60 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.438B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.637B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.181B | 21.51 |
| Lantheus Holdings (LNTH) | United States | $5.172B | 13.05 |
| Prestige Consumer Healthcare (PBH) | United States | $4.201B | 18.77 |
| Perrigo (PRGO) | Ireland | $3.629B | 9.20 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.218B | 23.73 |
| Haemonetics (HAE) | United States | $3.178B | 14.48 |
| Envista Holdings (NVST) | United States | $2.859B | 23.76 |
| GN Store Nord (GNNDY) | Denmark | $2.097B | 17.37 |
| QuidelOrtho (QDEL) | United States | $2.041B | 14.04 |
| LeMaitre Vascular (LMAT) | United States | $1.788B | 39.96 |
| AtriCure (ATRC) | United States | $1.624B | 0.00 |
| Neogen (NEOG) | United States | $1.343B | 17.19 |
| Acuren (TIC) | United States | $1.288B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.206B | 12.25 |
| Green Thumb Industries (GTBIF) | United States | $1.175B | 26.43 |
| Kestra Medical Technologies (KMTS) | United States | $1.145B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.050B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.933B | 11.93 |
| InMode (INMD) | Israel | $0.906B | 9.13 |
| CeriBell (CBLL) | United States | $0.624B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.584B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.558B | 0.00 |
| Owens & Minor (OMI) | United States | $0.532B | 4.41 |
| Valneva SE (VALN) | France | $0.529B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.496B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.450B | 0.00 |
| Surmodics (SRDX) | United States | $0.417B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.355B | 0.00 |
| SNDL (SNDL) | Canada | $0.344B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.336B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.318B | 11.71 |
| Aurora Cannabis (ACB) | Canada | $0.309B | 54.90 |
| Sanara MedTech (SMTI) | United States | $0.275B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.258B | 21.73 |
| Sanuwave Health (SNWV) | United States | $0.247B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.244B | 0.00 |
| Cerus (CERS) | United States | $0.239B | 0.00 |
| ZimVie (ZIMV) | United States | $0.233B | 10.57 |
| Biote (BTMD) | United States | $0.205B | 5.77 |
| Brainsway (BWAY) | Israel | $0.197B | 52.15 |
| OraSure Technologies (OSUR) | United States | $0.192B | 0.00 |
| High Tide (HITI) | Canada | $0.189B | 0.00 |
| Omeros (OMER) | United States | $0.189B | 0.00 |
| Quanterix (QTRX) | United States | $0.188B | 0.00 |
| Organigram Global (OGI) | Canada | $0.183B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.174B | 14.20 |
| TriSalus Life Sciences (TLSI) | United States | $0.173B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.131B | 16.18 |
| Exagen (XGN) | United States | $0.128B | 0.00 |
| Jin Medical (ZJYL) | China | $0.124B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.117B | 0.00 |
| Agape ATP (ATPC) | $0.112B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Fonar (FONR) | United States | $0.087B | 11.17 |
| Quipt Home Medical (QIPT) | United States | $0.075B | 0.00 |
| Veru (VERU) | United States | $0.072B | 0.00 |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Zynex (ZYXI) | United States | $0.070B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.064B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| United Health Products (UEEC) | United States | $0.051B | 0.00 |
| Modular Medical (MODD) | United States | $0.045B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.94 |
| Rockwell Medical (RMTI) | United States | $0.034B | 0.00 |
| Safety Shot (SHOT) | United States | $0.028B | 0.00 |
| Nephros (NEPH) | United States | $0.028B | 37.57 |
| Allurion Technologies (ALUR) | United States | $0.022B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |